NeoVirTech opens a new laboratory at the Toulouse Cancer Research Center (CRCT)
NeoVirTech SAS opens a new laboratory at the Toulouse Cancer Research Center (CRCT) to structure its anti-cancer programs towards the creation of a patient-oriented theranostics platform, and to promote drug development
NeoVirTech provides access to its ANCHORTM technology platform to develop disruptive models for the investigation of cancer-associated mechanisms and the preclinical development of oncolytic virotherapies.
More specifically, NeoVirTech and CRCT Team 10 aim to develop a rapid and reliable theranostic platform to ensure the efficacy of oncolytic virotherapies in cancer patients.
Long-term collaboration will ensure patient benefits and reduce the time to decision for individualised cancer therapies.
